Thank you, Mr. Chair.
I was doing some quick editing as the discussion was happening, so I will aim for the five minute or less approach to allow the maximum time for questions.
Mr. Chair, good morning. Thank you for having us back here today to support the committee’s continued study of the government’s response to the COVID-19 pandemic.
With me, as usual, is Ms. Arianne Reza, our assistant deputy minister of procurement. We are pleased to be here with our colleagues from the Public Health Agency of Canada. Our two organizations have been working very closely together during this crisis, with PSPC focusing on buying the personal protective equipment and medical supplies needed by health care professionals on the front lines.
At our last appearance here on April 24, we underscored the competitive, challenging environment for procurements on the global stage. That environment is one that we continue to operate in and, although it has changed to a certain extent, it continues to be challenging.
I will talk about our progress in a moment, but first let me speak to some of the challenges we continue to face.
As this committee well knows, most of the supplies in the world that we are seeking are manufactured in China. This means that we continue to receive product from unfamiliar suppliers, supply chains are strained and there are significant logistical issues that we continue to work through.
In China, on the ground, our supplies are steadily coming into our warehouse with more regularity. We are seeing the same regularity with cargo flights coming into Canada. In total, we are now up to 27 flights. As a rough order of magnitude, we are basically dealing with one flight a day. That's the essential rhythm we have hit right now, and we continue to build capacity on this front.
In the last week, we have seen a surge of materials arriving at our warehouse in China. To help with this surge, we contracted with UPS for additional temporary logistical supports on the ground in China with air cargo operations. This approach was instrumental in getting additional flights out of China during a very busy and difficult time.
Recently, we have also tried out a second airport in China. The initial flights from that second airport were successful, so it gives us an additional option going forward in using another airport in addition to Shanghai.
Mr. Chair, we have also been working with the Public Health Agency of Canada on developing an overall logistics solution to deal with large international shipments arriving by both sea and air, as well as domestic shipments arriving by vehicle. On May 4, we sent out an invitation to suppliers to submit an expression of interest to help us in this endeavour. That same day, we sent out a request for proposal for additional logistics supports at airports in China to increase our capacity in that supply chain.
Mr. Chair, when you look at the volume of supplies coming in now, you see that the vast majority have met Canadian requirements. However, as you know, we have had some issues with some products that did not meet agreed-upon standards. Notably, we received an order of approximately 11 million KN95 masks from one supplier, and about eight million of those masks did not meet the performance standards for the grade of that mask. We have since suspended all further shipments of these types of masks from that supplier. While many of these masks are fine for other uses, I want to reconfirm to this committee that none of these were distributed for medical use. As my colleagues from the Public Health Agency of Canada will tell you, only when products are deemed effective and safe are they distributed to the front lines.
Mr. Chair, I should also touch on what we're doing in domestic procurements. Since we last met, our department has finalized a long-term agreement with Medicom of Pointe-Claire, Quebec for the domestic production of 20 million N95 respirators and 24 million surgical masks a year over the next 10 years. A contract has been signed for 15 million face shields to be made by Sterling Industries out of Ontario, and we have a contract with Hewlett Packard to make over a half a million more. We have signed a new contract with Logistik Unicorp, a manufacturer out of Saint-Jean-sur-Richelieu, Quebec, and it is supplying us with more than 11 million medical gowns.
When it comes to testing for COVID-19, we have reached an agreement with a New Brunswick company, LuminUltra, to produce enough reagents, the critical chemical in testing, for about 500,000 tests per week right through March.
These are just a few recent examples.
Mr. Chair, in closing, this is a massive effort for the departments and we continue to shift resources to meet the needs of procurement for our front-line health care workers. We're mitigating the risks as best we can, learning lessons and making adjustments as we go. We are committed to continuing to work with our colleagues at the Public Health Agency of Canada and all of our partners to secure the necessary supplies.
Mr. Chair, because you wanted us to wrap up quickly, I'll leave it there. I look forward to your questions.